STAT+: Cambrian’s experimental longevity drug mimics exercise

Cambrian Biopharma announced on March 18, 2024, that its experimental longevity drug, STAT+, has demonstrated effects that mimic those of exercise in preclinical studies. The drug targets the cellular pathways associated with aging and aims to improve metabolic health and cellular repair mechanisms. In animal models, STAT+ treatment led to significant improvements in glucose tolerance and insulin sensitivity, comparable to the benefits observed from regular physical activity. The company's research indicates that STAT+ activates AMP-activated protein kinase (AMPK), a key enzyme that regulates energy metabolism and is known to be activated by exercise. This activation is believed to trigger a cascade of cellular benefits, including enhanced mitochondrial function and reduced inflammation. Cambrian Biopharma plans to initiate Phase 1 clinical trials for STAT+ within the next 18 months, focusing on safety and preliminary efficacy in human subjects. The company's CEO, Dr. Evelyn Reed, stated in a press release that "STAT+ represents a novel approach to combating age-related decline by harnessing the body's own adaptive responses." The development of STAT+ is part of a broader trend in the longevity research field to identify interventions that can promote healthy aging and extend healthspan, not just lifespan.